VANCOUVER, Sept. 9, 2019 /CNW/ - THC BioMed Intl Ltd. ("THC" or the "Company") (CSE: THC) announces that Health Canada has completed an inspection at its flagship Acland road facility.
"This inspection brings us a step closer to supplying adult Canadian Cannabis users with an alternative, brand-new product THC Kiss," commented John Miller, CEO of THC.
"We believe licensed producers need to be more innovative and invent their own brand of new products. These products need to be better than products currently available on the grey market, rather than copying and trying to compete with current illicit market products."
THC Kiss is a new, innovative Cannabis beverage invented by THC.
THC Kiss, when approved, will only be available through authorized provincial distributers as well as registered patients.
We further look forward to submitting a new product application in the next few days for approval to distribute our Automated Pure Cannabis Pre-Rolls.
THC is an ACMPR Licensed Producer and Canada's largest supplier of legal Cannabis Genetics. THC is on the leading edge of scientific research and the development of products and services related to the medical cannabis industry. Management believes THC is well-positioned to be in the forefront of this rapidly growing industry. Please visit our website for a more detailed description of our business and services available. www.thcbiomed.com
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC. Forward-looking information is based on certain key expectations and assumptions made by the management of THC. In some cases, you can identify forward-looking statements by the use of words such as "will," "may," "would," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "could" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Although THC believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release and include that (a) THC Kiss will be approved by Health Canada and available for purchase, (b) THC will submit a new product application in the next few days for approval to distribute its Automated Pure Cannabis Pre-Rolls, and (e) THC will be on the forefront of this rapidly growing industry. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.
SOURCE THC BioMed
For further information: President and CEO: John Miller, THC Biomed Intl Ltd., T: 1-844-THCMEDS, E: email@example.com